Logo Image
|Articles|November 18, 2020

INTERPHEX 2021 Rescheduled Due to COVID-19

The event will be rescheduled for Oct. 19–21, 2021 at the Javits Center in New York City.

Reed Exhibitions announced on Nov. 18, 2020 that it is rescheduling its pharmaceutical industry event INTERPHEX—previously postponed to April 20–22, 2021 at the Javits Center in New York City—to Oct. 19–21, 2021 at the same venue due to the continuing spread of COVID-19.

“After extensive consultation and ongoing monitoring of the COVID-19 pandemic, we have made this decision with the wellbeing of all our customers and partners as our highest priority,” said Marie Browne, group vice president, Reed Exhibitions, in a company press release. “We recognize and appreciate how important INTERPHEX is to the industry and to businesses. We are developing additional channels and digital tools to complement the live event in order to serve the industry, support our loyal exhibitors, and to ensure our attendees have access to find the solutions they need to cost effectively develop and manufacture quality products.”

Source: Reed Exhibitions

Related to this article

View more
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
China’s NMPA grants priority review to Akeso’s PD-1/VEGF bispecific ivonescimab with chemotherapy for first-line biliary tract cancer, VeonGen Therapeutics aligns with FDA on a phase 3 design for its dual-AAV Stargardt gene therapy VG801, and Caldera Therapeutics’ IL-23p19×TL1A bispecific CLD-423 shows a half-life of more than 40 days in a phase 1a trial.
Read more
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
Boehringer Ingelheim licenses six preclinical ADC and T-cell engager programs from Sino Biopharmaceutical in a deal worth up to $7 billion, Spyre Therapeutics drops anti-TL1A antibody SPY072 in rheumatic diseases after phase 2 misses and turns to hidradenitis suppurativa, and Biora Therapeutics gets ethics approval for a first-in-human trial of its BioJet oral adalimumab capsule.
Read more